Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtcvs.2016.02.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First evaluation of a novel pulsatile LVAD: Feasibility and haemodynamic impact in acute heart failure.
ESC Heart Fail
September 2025
Department of Cardiac-, Thoracic-, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Aims: Non-pharmacological therapies for acute decompensated heart failure (HF) and cardiogenic shock have evolved considerably in recent decades. Short-term mechanical circulatory support (MCS) devices can be used as circulatory backup. While nearly all available devices use continuous flow, evidence indicates that pulsatile flow can be more effective.
View Article and Find Full Text PDFLong Term Outcomes of Tricuspid Valve Repair or Replacement in Patients with Continuous Flow Left Ventricular Assist Devices.
J Thorac Cardiovasc Surg
September 2025
Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY. Electronic address:
Objective: Our objective was to determine the long-term outcomes of concomitant tricuspid valve procedures (TVP) during continuous-flow left ventricular assist device (LVAD) implantation.
Methods: We retrospectively reviewed patients who received HeartMate II or 3 from 2004 to 2023. Nine patients who had a previous TVP were excluded.
A Milestone in Cardiac Care in Iraq: One-year Follow-up after the Nation's First Continuous-flow Left Ventricular Assist Device Implantation, Paving the Way for Heart Transplantation.
Heart Views
July 2025
Department of Cardiac, Thoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
The first successful implantation of the HeartMate 3 LVAD in Iraq represents a transformative achievement in the nation's medical history. Conducted collaboratively by German and Iraqi teams in December 2023, the procedure addressed end-stage heart failure in a 60-year-old male. Despite significant healthcare challenges, the patient's functional status improved markedly, moving from New York Heart Association Class IV to Class I within a year.
View Article and Find Full Text PDFRisk prediction model for waitlist mortality in patients with left ventricular assist devices.
JHLT Open
November 2025
Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Background: Left ventricular assist devices (LVAD) are a bridge to heart transplantation (HT). Given limited donor organs, assessment of risk of waitlist mortality is important for waitlist prioritization for HT. We sought to derive and validate a risk prediction model for waitlist mortality in LVAD patients.
View Article and Find Full Text PDFPhysiologic effects of different hemodynamic patterns of LVAD.
Front Cardiovasc Med
August 2025
Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Left ventricular assist device (LVAD) is an important treatment for patients with end-stage heart failure, which essentially replaces the left ventricle's pumping action to improve peripheral circulation. Its hemodynamic pattern (pulsatile vs. continuous flow) has been a popular research topic in the field.
View Article and Find Full Text PDF